Sandra Ventorin von Zeidler

Prof. Dr. Sandra Ventorin von Zeidler

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HMHisham Mehanna
Hisham Mehanna
WWWai-Lup Wong
Wai-Lup Wong
CMChristopher C. McConkey
Christopher C. McConkey
JRJoy K. Rahman
Joy K. Rahman
MRMax Robinson
Max Robinson
JDJanet Dunn
Janet Dunn
The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate. In this prospective, randomized, controlled trial, we assessed the noninferiority of positron-emission tomography–computed tomography (PET-CT)–guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only if PET-CT showed an incomplete or equivocal response) to planned neck dissection in patients with stage N2 or N3 disease. The primary end point was overall survival. From 2007 through 2012, we recruited 564 patients (282 patients in the planned-surgery group and 282 patients in the surveillance group) from 37 centers in the United Kingdom. Among these patients, 17% had nodal stage N2a disease and 61% had stage N2b disease. A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that stained positive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer. The median follow-up was 36 months. PET-CT–guided surveillance resulted in fewer neck dissections than did planned dissection surgery (54 vs. 221); rates of surgical complications were similar in the two groups (42% and 38%, respectively). The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in the surveillance group and 81.5% (95% CI, 76.9 to 86.3) in the planned-surgery group. The hazard ratio for death slightly favored PET-CT–guided surveillance and indicated noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P=0.004). There was no significant difference between the groups with respect to p16 expression. Quality of life was similar in the two groups. PET-CT–guided surveillance, as compared with neck dissection, resulted in savings of £1,492 (approximately $2,190 in U.S. dollars) per person over the duration of the trial. Survival was similar among patients who underwent PET-CT–guided surveillance and those who underwent planned neck dissection, but surveillance resulted in considerably fewer operations and it was more cost-effective. (Funded by the National Institute for Health Research Health Technology Assessment Programme and Cancer Research UK; PET-NECK Current Controlled Trials number, ISRCTN13735240.)

1 September 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JBJill Mary Brooks
Jill Mary Brooks
AMAlbert Nobre Menezes
Albert Nobre Menezes
MIMaha Ibrahim
Maha Ibrahim
LALucinda Archer
Lucinda Archer
NLNeeraj Lal
Neeraj Lal
HMHisham Mehanna
Hisham Mehanna
Purpose: Intratumoural hypoxia and immunity have been correlated with patient outcome in various tumour settings. However, these factors are not currently considered for treatment selection in head and neck cancer (HNC) due to lack of validated biomarkers. Here we sought to develop a hypoxia-immune classifier with potential application in patient prognostication and prediction of response to targeted therapy. Experimental design: A 54-gene hypoxia-immune signature was constructed based on literature review. Gene expression was analysed in silico using the TCGA HNC dataset (n=275) and validated using two independent cohorts (n=130 and 123). Immunohistochemistry was used to investigate the utility of a simplified protein signature. The spatial distribution of hypoxia and immune markers was examined using multiplex immunofluorescence staining. Results: Unsupervised hierarchical clustering of TCGA dataset (development cohort) identified three patient subgroups with distinct hypoxia-immune phenotypes and survival profiles: hypoxialow/immunehigh, hypoxiahigh/immunelow and mixed, with 5-year overall survival (OS) rates of 71%, 51% and 49% respectively (p=0.0015). The prognostic relevance of the hypoxia-immune gene signature was replicated in two independent validation cohorts. Only PD-L1 and intratumoural CD3 protein expression were associated with improved OS on multivariate analysis. Hypoxialow/immunehigh and hypoxiahigh/immunelow tumours were over-represented in 'inflamed' and 'immune-desert' microenvironmental profiles respectively. Multiplex staining demonstrated an inverse correlation between CA-IX expression and prevalence of intratumoural CD3+ T cells (r=-0.5464, p=0.0377), further corroborating the transcription-based classification. Conclusion: We developed and validated a hypoxia-immune prognostic transcriptional classifier, which may have clinical application to guide the use of hypoxia modification and targeted immunotherapies for the treatment of HNC.

27 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PAPriscila Marinho de Abreu
Priscila Marinho de Abreu
ACAnna Clara Gregório Có
Anna Clara Gregório Có
PAPedro Leite Azevedo
Pedro Leite Azevedo
IVIsabella Bittencourt Do Valle
Isabella Bittencourt Do Valle
KOKarine Gadioli de Oliveira
Karine Gadioli de Oliveira
Sandra Ventorin von ZeidlerSandra Ventorin von Zeidler
Sandra Ventorin von Zeidler
The prevalence of high-risk human papillomavirus (HPV) DNA in cases of oral cavity squamous cell carcinoma (SCC) varies widely. The aim of this study is to investigate the frequency of high-risk HPV DNA in a large Brazilian cohort of patients with oral cavity SCC. Biopsy and resected frozen and formalin-fixed paraffin-embedded specimens of oral cavity SCC were available from 101 patients who were recruited at two Brazilian centres. Stringent measures with respect to case selection and prevention of sample contamination were adopted to ensure reliability of the data. Nested PCR using MY09/MY11 and GP5+/GP6+ as well as PGMY09/11 L1 consensus primers were performed to investigate the presence of HPV DNA in the tumours. HPV-positive cases were subjected to direct sequencing. Shapiro–Wilk and Student t test were used to evaluate data normality and to compare the means, respectively. Qualitative variables were analysed by logistic regression. Our results demonstrate that the frequency of high-risk HPV types in oral cavity SCC is very low and is less than 4%. All HPV-positive cases were HPV16. In addition, our results do not show a significant association between the tumour clinical features and the risk factors (tobacco, alcohol and HPV) for oral cavity SCC. In the current study, we observed an overlapping pattern of risk factors that are related to tumour development. This, along with a low frequency of high-risk HPV DNA, supports the findings that HPV is not involved in the genesis of oral cavity SCC in Brazilian population.

17 December 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Sandra Ventorin von ZeidlerSandra Ventorin von Zeidler
Sandra Ventorin von Zeidler
TBTalitha de Souza Botelho
Talitha de Souza Botelho
EMElismauro Francisco Mendonça
Elismauro Francisco Mendonça
ABAline Carvalho Batista
Aline Carvalho Batista
Numerous attempts have been made to establish and develop tumor markers that could determine the susceptibility of normal tissues to transform into cancerous ones. To determine whether altered expression patterns of E-cadherin could be an early event in the progression of potentially malignant disorders to oral squamous cell carcinoma, this study aimed to assess the relationship between the immunoexpression of E-cadherin and the different degrees of epithelial dysplasia in oral leukoplakia.

24 January 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KOKarine G Oliveira
Karine G Oliveira
Sandra Ventorin von ZeidlerSandra Ventorin von Zeidler
Sandra Ventorin von Zeidler
JPJose Rv Podestá
Jose Rv Podestá
ASAgenor Sena
Agenor Sena
ESEvandro D Souza
Evandro D Souza
SGSonia Gouvea
Sonia Gouvea
Background: The aim of this study was to assess the severity of pain and its impact on the quality of life (QoL) in untreated patients with head and neck squamous cell carcinoma (HNSCC).Methods: A study group of 127 patients with HNSCC were interviewed before antineoplastic treatment. The severity of pain was measured using the Brief Pain Inventory (BPI) questionnaire, and the QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) and the head and neck module (QLQ-H&N35).Results: The mean age of the patients was 57.9 years, and there was a predominance of men (87.4%). The most frequent site of the primary tumor was the oral cavity (70.6%), and the majority of the patients had advanced cancers (stages III and IV). QoL in early stage of cancer obtained better scores. Conversely, the patients with advanced stage cancer scored significantly higher on the symptom scales regarding fatigue, pain, appetite loss and financial difficulties, indicating greater difficulties. Regard to the severity of pain, patients with moderate-severe pain revealed a significantly worse score than patients without pain.Conclusions: The severity of pain is statistically related to the advanced stages of cancer and directly affects the QoL. An assessment of the quality of life and symptoms before therapy can direct attention to the most important symptoms, and appropriate interventions can then be directed toward improving QoL outcomes and the response to treatment.

31 March 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LTLaura Torrens
Laura Torrens
SMSarah Moody
Sarah Moody
ACAna Carolina de Carvalho
Ana Carolina de Carvalho
MKMariya Kazachkova
Mariya Kazachkova
BABehnoush Abedi-Ardekani
Behnoush Abedi-Ardekani
SPSandra Perdomo
Sandra Perdomo
Tobacco smoke, alone or combined with alcohol, is the predominant cause of head and neck cancer (HNC). We explore how tobacco exposure contributes to cancer development by mutational signature analysis of 265 whole-genome sequenced HNC samples from eight countries. Six tobacco-associated mutational signatures were detected, including some not previously reported. Differences in HNC incidence between countries corresponded with differences in mutation burdens of tobacco-associated signatures, consistent with the dominant role of tobacco in HNC causation. Differences were found in the burden of tobacco-associated signatures between anatomical subsites, suggesting that tissue-specific factors modulate mutagenesis. We identified an association between tobacco smoking and alcohol-related signatures, indicating a combined effect of these exposures. Tobacco smoking was associated with differences in the mutational spectra, repertoire of driver mutations in cancer genes and patterns of copy number change. Our results demonstrate the multiple pathways by which tobacco smoke can influence the evolution of cancer cell clones.